Propionic Acidemia
Autosomal recessive metabolic disorder caused by mutations in PROPIONYL-COA CARBOXYLASE genes that result in dysfunction of branch chain amino acids and of the metabolism of certain fatty acids. Neonatal clinical onset is characterized by severe metabolic acidemia accompanied by hyperammonemia, HYPERGLYCEMIA, lethargy, vomiting, HYPOTONIA; and HEPATOMEGALY. Survivors of the neonatal onset propionic acidemia often show developmental retardation, and intolerance to dietary proteins. Late-onset form of the disease shows mild mental and/or developmental retardation, sometimes without metabolic acidemia.
Drugs by status
Phase 3 trials (2)
Phase 1 trials (4)
Other trials (3)
Organizations
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (13)
- Moderna Therapeutics
- National Institutes of Health (NIH)
- Children's National Research Institute
- University of Pennsylvania
- University of Pittsburgh
- Case Western Reserve University
- Harvard University
- Stanford University
- University of California, Los Angeles
- University of Colorado, Denver
- Icahn School of Medicine at Mount Sinai
- Children's National Medical Center
- University of Colorado
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (1)